Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC, page-37

@bavarian1975

@davybabyk

Few questions about the graph, wondering if you can shed some light ...

1. If the lines are showing antibody levels in patients over time, shouldn't there be a line for each patient on the trial - ie 14 lines?

2. Do the green and yellow lines that run along the x-axis mean that no antibody effect was observed in those patients? If so can disease progression (or lack thereof) in those patients be attributed to IMU-201?

3. Is it pointless to try to make any efficacy conclusions based on this Phase 1(a) trial? Are we just saying that (a) antibody levels are achieved with the 100ug dose and (b) dosing with 100ug is relatively safe, so its worth proceeding with the Phase 1(b) trial to see if in combination we get some efficacy indications?

Not trying to downplay results, just trying to understand them ...

Thanks in advance.